Home » Stocks » STXS

Stereotaxis, Inc. (STXS)

Stock Price: $4.36 USD -0.38 (-8.02%)
Updated Jan 27, 2021 11:57 AM EST - Market open
Market Cap 348.53M
Revenue (ttm) 26.70M
Net Income (ttm) -7.94M
Shares Out 74.49M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $4.36
Previous Close $4.74
Change ($) -0.38
Change (%) -8.02%
Day's Open 4.65
Day's Range 4.36 - 4.69
Day's Volume 144,216
52-Week Range 1.77 - 5.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 2 months ago

Stereotaxis, Inc. (STXS) CEO David Fischel on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

Stereotaxis, Inc.'s (STXS) CEO David Fischel on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

ST. LOUIS, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial r...

GlobeNewsWire - 3 months ago

ST. LOUIS, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it wi...

GlobeNewsWire - 4 months ago

ST. LOUIS, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it ha...

GlobeNewsWire - 4 months ago

ST. LOUIS, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that ...

GlobeNewsWire - 4 months ago

ST. LOUIS, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that D...

GlobeNewsWire - 5 months ago

ST. LOUIS, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a pion...

Seeking Alpha - 5 months ago

Stereotaxis, Inc. (STXS) CEO David Fischel on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

ST. LOUIS, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financi...

GlobeNewsWire - 5 months ago

ST. LOUIS and CARLSBAD, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Acutus Medical today announced the first integrated cardiac ablation procedure benefiting f...

GlobeNewsWire - 6 months ago

ST. LOUIS, July 23, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that i...

GlobeNewsWire - 6 months ago

ST. LOUIS, July 13, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publ...

GlobeNewsWire - 7 months ago

ST. LOUIS, June 22, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that t...

InvestorPlace - 7 months ago

Robotics stocks offer multi-decade growth potential. These 10 stocks offer some of the best exposure to this attractive trend.

Other stocks mentioned: ABB, AVAV, BOTZ, FLIR, GMED, IRBT, ISRG, TRMB
GlobeNewsWire - 7 months ago

ST. LOUIS, June 18, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that D...

GlobeNewsWire - 7 months ago

ST. LOUIS, June 02, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has...

GlobeNewsWire - 8 months ago

ST. LOUIS, May 26, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it h...

Seeking Alpha - 8 months ago

Stereotaxis, Inc. (STXS) CEO David Fischel on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

Stereotaxis, Inc. (STXS) CEO David Fischel on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

ST. LOUIS, March 06, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today it has ...

Seeking Alpha - 1 year ago

Stereotaxis: A Small But Stellar Performer In The Medical Robotics Space

Seeking Alpha - 1 year ago

Stereotaxis: Poised For A Strong 2020

GlobeNewsWire - 1 year ago

ST. LOUIS, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that H...

The Motley Fool - 1 year ago

A series of financial missteps led to a delisting for Stereotaxis in 2013. Now that a new CEO has made some progress toward a turnaround, the robotic technology company may deserve a second ch...

Seeking Alpha - 1 year ago

Stereotaxis, Inc. (STXS) CEO David Fischel on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

ST. LOUIS and MT. OLIVE, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and Catheter Precision today announced the first patients have been successfully treate...

GlobeNewsWire - 1 year ago

ST. LOUIS and PESSAC, France, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and inHEART today announced the first patients have been successfully treated with the i...

GlobeNewsWire - 1 year ago

ST. LOUIS and BARCELONA, Spain, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS) and ADAS 3D Medical SL today announced the first patients have been successfully treat...

The Motley Fool - 1 year ago

Accuray and Stereotaxis are hyper-focused on growth.

Other stocks mentioned: ARAY, ISRG, MDT, SYK, VAR
GlobeNewsWire - 1 year ago

ST. LOUIS, Mo., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today a...

About STXS

Stereotaxis designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system that offers navig... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Aug 12, 2004
CEO
David Fischel
Employees
118
Stock Exchange
NYSEAMERICAN
Ticker Symbol
STXS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Stereotaxis stock is "Strong Buy." The 12-month stock price forecast is 7.33, which is an increase of 68.12% from the latest price.

Price Target
$7.33
(68.12% upside)
Analyst Consensus: Strong Buy